ArticleScientific reports2025
Plasma biomarker ORAI1 as a dual prognostic value for survival and postoperative quality of life in glioma patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gliomas represent one of the most common and highly malignant primary brain tumors, with overall prognosis remaining unsatisfactory to date. Although certain molecular biomarkers have been identified to stratify patients based on survival outcomes, non-invasive blood biomarkers capable of simultaneously predicting both survival prognosis and postoperative quality of life (QoL) are still lacking. This study provides substantial evidence for the potential of ORAI1 as a non-invasive biomarker across diverse ethnic clinical cohorts. This investigation employed a translational medicine-oriented exploratory approach, incorporating 309 glioma patients from the Chinese Glioma Genome Atlas (CGGA) and 563 patients from The Cancer Genome Atlas (TCGA). Additionally, preoperative plasma samples from 50 glioma patients were analyzed by ELISA, alongside postoperative QoL assessments within three days after surgery. The correlations between ORAI1 gene expression and patients' survival outcomes as well as postoperative QoL were evaluated, with further exploration of potential underlying biological mechanisms. High ORAI1 expression was identified as an independent adverse prognostic factor in glioma patients, significantly enriched in those with higher WHO grades (III-IV). Patients in the high ORAI1 expression group exhibited increased postoperative pain scores and poorer sleep quality. Notably, ORAI1 expression was absent or minimal in glioma tissues but markedly elevated in patients' preoperative plasma. Functional enrichment analyses including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Variation Analysis (GSVA) indicated the potential utility of ORAI1 as a peripheral blood biomarker. ORAI1 serves not only as an independent predictor of survival prognosis but also reflects postoperative QoL, representing a promising dual biomarker. The discordant expression of ORAI1 in tumor tissue versus plasma suggests a unique role in tumor-host system interactions. These findings suggest new directions for precise prognostic evaluation and personalized perioperative management in glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.